Sanofi To Advance Kymera’s IRAK4 Protein Degrader After Phase I Success
But Some Analysts Advise Caution
Executive Summary
The French major is planning a Phase II trial of KT-474 in atopic dermatitis and hidradenitis suppurativa after the asset fared well in a small Phase I trial, although some analysts remain skeptical.
You may also be interested in...
Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I
Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.
From Hengrui To Moderna: Why More Biotech Companies Are Creating Swiss Hubs
An increasing number of biotech companies originating from the US and Asia are building EU headquarters in Switzerland. Scrip spoke with four key opinion leaders on the motivations behind these decisions and the role the domestic ecosystem has to play, from school systems to neutral politics and beyond.
AstraZeneca’s IBD Hopes Deflated Amid Evolving Market And Pipeline Competition
The major’s attempt to break into Crohn’s disease and ulcerative colitis has been cut short as a highly competitive market and pipeline, intensified by the entrance of biosimilars, renders further development of brazikumab impractical.